Pricing Log in Create free account

Incyte Corporation (INCY) vs Revolution Medicines, Inc. (RVMD)

Incyte Corporation and Revolution Medicines, Inc. are both Biotechnology companies. Revolution Medicines, Inc. is the larger, with a market value of $40.6B against $23.0B — 1.8× the size. Revolution Medicines, Inc. has negative trailing earnings, so its P/E is not meaningful; Incyte Corporation trades at 13.9×. Incyte Corporation grew revenue faster over the last twelve months: 26.9% against −8.81%. Incyte Corporation has the higher net margin (27.7% vs 0.00%) and the higher return on invested capital (60.5% vs 0.00%). Across the 18 metrics below, Incyte Corporation leads on 17 and Revolution Medicines, Inc. on 1.

Valuation

Metric INCY RVMD Biotechnology median
P/E 13.89 n/m 8.50
P/S 3.89 1,394.67 9.71
P/B 3.57 14.40 2.13
Price to free cash flow 11.97 n/m 20.82
EV/EBITDA 9.66 n/m 0.64
EV/Sales 3.12 1,286.83 9.21
Earnings yield 7.20% (4.96%) (33.15%)
Free cash flow yield 8.35% (3.28%) (25.50%)

Profitability

Metric INCY RVMD Biotechnology median
Gross margin 92.62% 35.06% 65.16%
Operating margin 30.56% 0.00% 0.00%
Net margin 27.71% 0.00% 0.00%
Free cash flow margin 32.48% 0.00% 0.00%
Return on equity 30.67% (79.09%) (56.36%)
Return on assets 23.55% (52.37%) (48.04%)
Return on invested capital 60.50% 0.00% 0.00%

Growth

Metric INCY RVMD Biotechnology median
Revenue growth (TTM) 26.93% (8.81%) 6.02%
EPS growth (last fiscal year) 4,173.33% (66.20%) 30.26%
Revenue growth, 5-year CAGR 14.03% (10.50%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INCY RVMD Biotechnology median
Debt to equity 0.00 0.40 0.00
Current ratio 4.59 11.38 4.72
Net debt to EBITDA (2.21) 1.47 0.96

Dividend

Metric INCY RVMD Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric INCY RVMD Biotechnology median
Market cap 22.96b 40.57b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack